Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Charlene M. Flowers"'
Publikováno v:
Neurology. 90:e1548-e1552
ObjectiveTo evaluate acute acalculous cholecystitis (AAC) as a potential safety risk for patients treated with alemtuzumab.MethodsThe Food and Drug Administration Adverse Event Reporting System and the medical literature were searched for cases of AA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da8ff7322c590649dc70260035bb97ac
https://doi.org/10.1212/wnl.0000000000005422
https://doi.org/10.1212/wnl.0000000000005422
Autor:
Yi Tsong, Min Chen, Feng Zhou, David A. Flockhart, Denise Toyer, Curtis Rosebraugh, Charlene M. Flowers, Ann Corken Mackey, Peter K. Honig
Publikováno v:
Pharmacoepidemiology and Drug Safety. 12:97-101
Purpose Evaluate whether a 15-minute lecture intervention will improve adverse drug reaction reporting quality on standard MedWatch forms. Methods Seventy-eight 4th-year medical students were randomized to intervention ‘Group-A’ or non-interventi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e62ec8311063a0158a47235221527c1
https://doi.org/10.1002/pds.797
https://doi.org/10.1002/pds.797
Publikováno v:
Alimentary Pharmacology & Therapeutics.
Aliment Pharmacol Ther 31, 1028–1035 Summary Background Natalizumab is a recombinant monoclonal antibody approved for the treatment of patients with multiple sclerosis and patients with Crohn’s disease. Because of its immunosuppressive effects, n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f1c5a7b4e124ce8dd71d8243fe4a596
https://doi.org/10.1111/j.1365-2036.2010.04262.x
https://doi.org/10.1111/j.1365-2036.2010.04262.x
Publikováno v:
Pediatric neurology. 37(2)
Oxcarbazepine, a carbamazepine analog, was approved for use as an antiepileptic agent in the United States in 2000. A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faff35de37c703fbdfd5e06c3af8c0a5
https://pubmed.ncbi.nlm.nih.gov/17675030
https://pubmed.ncbi.nlm.nih.gov/17675030
Publikováno v:
New England Journal of Medicine. 354:773-774
To the Editor: Thirty-one case reports of new-onset seizures associated with off-label use of tiagabine (Gabitril) have prompted the addition of a boldface warning to the product label.1 (Tiagabine is approved by the Food and Drug Administration [FDA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9351ccdf7fd665934559a49c62514c21
https://doi.org/10.1056/nejmc055301
https://doi.org/10.1056/nejmc055301
Publikováno v:
Mayo Clinic Proceedings. 78:730-731
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79774a4f9bea300d9a4689e32f6da1de
https://doi.org/10.4065/78.6.730
https://doi.org/10.4065/78.6.730